Insulin Still Unattainable for Many Living with Diabetes Worldwide: ACCISS Study Review in The Lancet D&E


An ACCISS Study Review of the global insulin market, called ‘Constraints and Challenges in Access to Insulin: A Global Perspective, was published Friday in The Lancet Diabetes & Endocrinology. Co-authored by ACCISS Study leaders, David Beran, Marg Ewen and Richard Laing, the Review describes why insulin is still unattainable for approximately half of all people who need it.

The EU-US Trade Deal Could Leave Europeans Sick

Some help us for a while. Some cure us entirely. No doubt, medicines—when they’re available and affordable—play a crucial role in helping us live better quality and longer lives than ever before. So, why, then, would the European Commission do anything that would risk citizens’ ability to access the medicines we need?

HAI Launches Innovative Global Study to Improve Access to Insulin

by MARG EWEN, Global Pricing Co-ordinator and ACCISS Study Co-investigator

The global need for insulin, a hormone that converts sugar, starches and other food into needed energy for everyday activities, is immense. An estimated 100 million people with diabetes need it. This includes all with type 1 diabetes, plus 20 to 30 per cent of people with type 2 diabetes.

New materials help assess medicines policies and interventions


Many countries, no matter their geographic region or level of economic development, have tremendous opportunity to improve medicines prices, availability and affordability for their citizens. To aid in this endeavour, various medicines policies and interventions exist. It can be difficult, however, for countries to determine which policies and interventions to implement;

DG Trade State of Play reveals EU's ambitions for IP protection in FTAs

The EU will not be changing its aggressive approach to IP protection in bilateral trade agreements, according to the updates that representatives from the European Commission gave at a State of Play meeting with civil society on June 27, 2011. Despite years of opposition and outrage by the global public health community, the EU continues to pursue high IP standards in trade deals with developing countries.

Report exposes how Big Pharma has hijacked EU-India trade deal

The livelihoods of millions of patients are at risk under the terms of a new trade deal being negotiated by the EU and India which has been hijacked by big business, highlights a new joint report from Corporate Europe Observatory and India FDI.

Trade Invaders – How big business is driving the EU-India free trade negotiations

HAI hosts essay competition for students

Health Action International (HAI) Europe is sponsoring an essay competition open to residents in Europe who are in, or have completed, full-time highereducation in the last eight years. The essay should focus on one of the principle areas of HAI Europe’s policy work:

Rational use of medicines

Access to essential medicines

Democratisation of medicines’ policy

Winning entries will be selected by a panel of referees and announced at the end of June.

Generic prescribing policies 1 – ABPI 0

The Association of the British Pharmaceutical Industry (ABPI) has lost a legal battle against schemes promoted by Britain’s state health service that encourage doctors to prescribe cheaper medicines.

The European Court of Justice has decided that public authorities may offer financial incentives to induce doctors to prescribe cheaper medicinal products. And that such incentives are not to be considered advertising,